Eye injection shows promise for Diabetes-Related vision loss
NCT ID NCT04597918
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called faricimab (VABYSMO) in people with diabetic macular edema, a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. Participants receive injections of faricimab into the eye every four weeks. The goal is to see how the drug affects vision and eye structure, and to find biological markers that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
faricimab (VABYSMO)
What this could lead to
If successful, this could help identify which patients with diabetic macular edema respond best to faricimab, potentially leading to more personalized treatment.
What could go wrong
This is an early-phase, single-arm study with no comparison group, so results may not confirm effectiveness. The treatment involves regular eye injections, which carry risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Research Center for Retina
Austin, Texas, 78705, United States
-
Bascom Palmer Eye Institute
Naples, Florida, 34103, United States
-
Centro Oftalmologico Dr. Charles S.A.
Capital Federal, C1116, Argentina
-
Charles Retina Institute
Germantown, Tennessee, 38138, United States
-
Cumberland Valley Retina PC
Hagerstown, Maryland, 21740, United States
-
Gloucestershire Hospitals NHS Foundation Trust
Gloucestershire, GL1 3NN, United Kingdom
-
Irccs Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
-
Kings College Hospital
London, SE5 9RS, United Kingdom
-
Long Is. Vitreoretinal Consult
Great Neck, New York, 11021, United States
-
Northwestern Medical Group/Northwestern University
Chicago, Illinois, 60611, United States
-
Oftalmos
Capital Federal, C1120AAN, Argentina
-
Ospedale San Giuseppe
Milan, Lombardy, 20123, Italy
-
Raj K. Maturi, MD PC
Indianapolis, Indiana, 46290, United States
-
Retina Consultants of Texas
Houston, Texas, 77030, United States
-
Retina Institute of Ottawa
Ottawa, Ontario, K2B 7E9, Canada
-
Retina Res Institute of Texas
Abilene, Texas, 79606, United States
-
Strategic Clinical Research Group, LLC
Willow Park, Texas, 76087, United States
-
Sunderland Eye Infirmary
Sunderland, SR2 9HP, United Kingdom
-
The Retina Institute
St Louis, Missouri, 63128, United States
-
Universitatsklinikum Tubingen
Tübingen, 72076, Germany
-
University Retina and Macula Associates, PC
Oak Forest, Illinois, 60452, United States
-
Vitreous Retina Macula Specialists of Toronto
Etobicoke, Ontario, M8X 2X3, Canada
-
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy
Warsaw, 04-141, Poland